PDF icon Download PDF
Semin Liver Dis 2024; 44(01): 054-068
DOI: 10.1055/a-2253-9181
Review Article

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Mohamed El-Kassas
1   Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt
2   Steatotic Liver Disease Study Foundation in Middle East and North Africa (SLMENA), Cairo, Egypt
,
Abeer Awad
3   Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt
,
Mohamed Elbadry
1   Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt
2   Steatotic Liver Disease Study Foundation in Middle East and North Africa (SLMENA), Cairo, Egypt
,
Juan Pablo Arab
4   Division of Gastroenterology, Department of Medicine, Schulich School of Medicine, Western University and London Health Sciences Centre, London, Ontario, Canada
5   Department of Epidemiology and Biostatistics, Schulich School of Medicine, Western University, London, Ontario, Canada
6   Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
› Author Affiliations
Funding None.
› Further Information
   Permissions and Reprints


Preview

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is increasing globally, creating a growing public health concern. However, this disease is often not diagnosed, and accurate data on its epidemiology are limited in many geographical regions, making it challenging to provide proper care and implement effective national plans. To combat the increasing disease burden, screening and diagnosis must reach a significant number of high-risk subjects. Addressing MASLD as a health care challenge requires a multidisciplinary approach involving prevention, diagnosis, treatment, and care, with collaboration between multiple stakeholders in the health care system. This approach must be guided by national and global strategies, to be combined with efficient models of care developed through a bottom-up process. This review article highlights the pillars of the MASLD model of care (MoC), including screening, risk stratification, and establishing a clinical care pathway for management, in addition to discussing the impact of nomenclature change on the proposed MoC.

Keywords

Metabolic dysfunction-associated steatotic liver disease - steatotic liver disease - nonalcoholic fatty liver disease - risk stratification - model of care

Author Contributions

M.E.K. and A.A. contributed to this paper with the conception and design of the work and literature review. A.A. wrote the first draft of the manuscript. M.E.K., M.E., and J.P.A. provided critical revision and editing. All authors revised and approved the final version of the manuscript.




Publication History

Accepted Manuscript online:
25 January 2024

Article published online:
21 February 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA